1822-57-7

Usage

Uses

Used in Pharmaceutical Industry:
4-(ChloroMethyl)quinoline hydrochloride is used as a synthetic intermediate for the development of new drug compounds due to its unique structure and reactivity, which allows for the creation of a variety of biologically active molecules.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(ChloroMethyl)quinoline hydrochloride is used as a reagent to facilitate the formation of various organic compounds, taking advantage of its chloromethyl group for functional group transformations and the synthesis of complex organic molecules.
Used in Research and Development:
4-(ChloroMethyl)quinoline hydrochloride is employed as a research tool in academic and industrial laboratories, where its properties are explored for potential applications in the discovery of new chemical reactions and the development of novel synthetic pathways.
Used in Drug Discovery:
As a building block in drug discovery, 4-(ChloroMethyl)quinoline hydrochloride is used to construct potential drug candidates, leveraging its reactivity and structural features to create molecules with desired pharmacological properties.

Upstream product

• 6281-32-9 4-quinolylmethanol 
• 60-29-7 diethyl ether 
• 142910-39-2 4-(hydroxymethyl)quinoline hydrobromide 
• 4363-93-3 quinoline-4-carboxaldehyde 

Downstream Products

• 675185-84-9 1-{[4(quinolin-4-ylmethoxy)phenyl]sulphanyl}acetone 
• 149326-24-9 4-(4-quinolinylmethoxy)benzaldehyde 

Relevant academic research and scientific papers

SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A)

The invention relates to compounds of the formula wherein R′, R1, through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.

BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-α Converting Enzyme (TACE). The compounds are useful in the

Lactam metalloprotease inhibitors

The present application describes novel lactams and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings ring B is a 4-8 membered cyclic amide containing from 0-3 additional heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.

Amino acid analogs as CCK antagonists

Novel unnatural dipeptoids useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. The compounds are agents useful for preventing the response to withdrawal from chronic treatment or use of nicotine, diazepam, alcohol, cocaine, caffeine, and opioids. The compounds are also useful in treating and/or preventing panic attacks. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare diagnostic compositions.

SUBSTITUTED QUINOLINYL AND NAPHTHALENYLBENZAMIDES OR BENZYLAMINES AND RELATED COMPOUNDS USEFUL AS ANALGESICS

This invention relates to novel quinolinyl-and naphthalenylbenzamides or benylamines and related disclosed compounds of the formula STR1 wherein X is nitrogen, NO or CR 1 ; Y is C(R 1)(R 2)O, OC(R. sup.1)(R 2), C(R 1)(R 2)N(R 3), N(R. sup.3)C(R 1)(R. sup.2) or C(R 1)=C(R 2); wherein R 1, R 2, and R 3 are independently hydrogen or lower alkyl containing 1 to 10 carbon atoms; Z is oxygen or (R 1)(R 2); R 4 is R 1, benzyl, benzyl ring substituted with R 5, benzyl alpha monosubstituted with R. sup.1, benzyl ring substituted with R 5 and alpha monosubstituted with R 1, phenyl, phenylalkyl containing 2 to 10 carbon atoms in the alkyl group or phenylalkyl ring substituted with R. sup.5 and containing 2 to 10 carbon atoms in the alkyl group; wherein R. sup.5 is R 1, lower alkoxy containing 1 to 10 carbon atoms, halogen, trihalomethyl, NO 2, N(R 1)(R 2) or C(O)N(R 1)(R 2); R 6 is R 1 or R. sup.6 is C(O)(R 7) with the proviso that Z is not oxygen; and wherein R 7 is R 1, phenyl, perfluoroalkyl containing 1 to 10 carbon atoms, phenylalkyl containing 1 to 10 carbon atoms in the alkyl group; or a pharmaceutically acceptable acid addition salt thereof, and their use in the treatment of pain mediated by the biological peptide, bradykinin. In particular, the preferred compounds are where X is nitrogen, and Y is CH 2 O of the above structure.